The proportion of patients with thrombocytopenia in three human‐susceptible coronavirus infections: a systematic review and meta‐analysis

Zhou, Meng; Qi, Jiaqian; Li, Xue–Qian; Zhang, Ziyan; Yao, Yifang; Wu, Depei; Han, Yue

doi:10.1111/bjh.16655

Cited by 18 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hematological abnormalities, such as thrombocytopenia, reduced numbers of peripheral blood lymphocytes and eosinophils with an increased polymorphonuclear-to-lymphocyte ratio are common features of novel coronavirus disease 2019 (COVID- 19), especially in more severe cases [1][2][3][4][5][6][7]. To date, no reports specifically addressed the investigation of anemia in COVID-19, with determination of its prevalence, pathogenesis and prognostic significance.…”

Section: Introductionmentioning

confidence: 99%

“…To date, no reports specifically addressed the investigation of anemia in COVID-19, with determination of its prevalence, pathogenesis and prognostic significance. The results from published case series are often conflicting, with some papers reporting similar hemoglobin (Hb) concentrations in patients who survived and those who died because of SARS-CoV-2 infection [1], or in intensive care unit (ICU) compared with non-ICU patients [5], whereas others reported lower Hb levels in patients with more severe disease [8]. Recent case reports described the association of COVID-19 with autoimmune hemolytic anemia (AHA), including one case of cold agglutinin disease AHA [9], but cases of AHA in COVID-19 are probably uncommon, and it is still unknown if AHA prevalence is higher in COVID-19 than in the general population [10,11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anemia in patients with Covid-19: pathogenesis and clinical significance

Bergamaschi¹,

Andreis

Aronico³

et al. 2021

Clin Exp Med

113

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anemia in patients with Covid-19: pathogenesis and clinical significance

Bergamaschi¹,

Andreis

Aronico³

et al. 2021

Clin Exp Med

113

View full text Add to dashboard Cite

“…This is the first study to characterize the COVID-19 patients with dynamic changes of coagulation and platelet functions that showed biological significance and variation in non-severe and severe groups. In severe patients, platelet levels were significantly lower than non-severe patients at admission, 1 week and 2 weeks after admission [5,6]. Severe patients also had higher white cell levels, but hemoglobin was not different between two groups at admission.…”

Section: Discussionmentioning

confidence: 78%

SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients

Bao

Tao²,

Cui

et al. 2020

Exp Hematol Oncol

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease, which lacks well-established diagnostic laboratory parameters that could be used to evaluate disease severity, thromboembolism or cardiovascular events and to predict clinical prognosis. Coagulation cascade and platelet functions have not been well studied in the COVID-19 patients. Methods: A total of 178 patients enrolled in Wuhan Huoshenshan Hospital were included for the study. Blood platelets and coagulation functions were analyzed in COVID-19 patients with non-severe and severe subgroups. Other biochemical laboratory parameters were also analyzed. Results: Forty-nine (27.5%) out of 178 patients were diagnosed with severe disease in this study, and 129 patients with non-severe disease. Severe disease group had significant lower platelet count 186.00 (103.50-249.00) ×10 9 /L than 251.00 (202.00-317.00) ×10 9 /L of non-severe group, p = 0.000. Severe group also had significantly abnormal coagulation parameters than non-severe group: prothrombin time (PT) 14.55 (13.40-16.53) s vs. 12.70 (12.15-13.59) s, p = 0.000; international normalized ratio (INR) 1.21 (1.13-1.36) vs. 1.06 (1.01-1.13), p = 0.000; thrombin time (TT) 16.35 (15.69-17.47) s vs. 15.68 (14.79-16.69) s, p = 0.011; D-Dimer 1.05 (0.68-5.90) mg/L vs. 0.42 (0.28-0.79) mg/L, p = 0.000; While the liver function parameter alanine aminotransferase (ALT) and aspartate aminotransferase (AST) didn't show significance between two groups, ALT 30.80 (19.00-58.30) IU/L vs. 28.80 (15.75-50.15) IU/L, p = 0.487; AST 27.80 (19.30-40.55) IU/L vs. 22.6 (16.7-32.03) IU/L, p = 0.102. Disseminated intravascular coagulation (DIC) rate was 6.1% in severe group while 0% in non-severe group. Survival rate of severe disease group was worse than non-severe group, 85.7% vs. 100%, p = 0.000. Thrombocytopenia correlated with coagulation function, DIC rate and survival. Six out of 7 death case had thrombocytopenia during hospitalization, and platelet count decreased subsequently until death.

show abstract

“…Although some drugs such as hydroxychloroquine are integrated in treatment guidelines or under investigation in interventional studies, the management of COVID-19 is mostly supportive. [2][3][4] Identifying biological abnormalities induced by COVID-19 may contribute to a better understanding of the pathophysiology of the disease and ultimately guide the development of targeted adjuvant therapies besides antivirals drugs. Furthermore, such information on the biological profile of COVID-19 can guide clinicians in the assessment and treatment of these patients.…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)

et al. 2020

View full text Add to dashboard Cite

Background: Prognostic factors for the Coronavirus disease 2019 (COVID1-9) are not well established. This study aimed to summarize the available data on the association between the severity of COVID-19 and common hematological, inflammatory and biochemical parameters. Methods: EMBASE, MEDLINE, Web of sciences were searched to identify all published studies providing relevant data. Random-effects meta-analysis was used to pool effect sizes. Results: The bibliographic search yielded 287 citations, 31 of which were finally retained. Meta-analysis of standardized mean difference (SMD) between severe and non-severe COVID-19 cases showed that CK-MB (SMD = 0.

show abstract

The proportion of patients with thrombocytopenia in three human‐susceptible coronavirus infections: a systematic review and meta‐analysis

Cited by 18 publications

References 23 publications

Anemia in patients with Covid-19: pathogenesis and clinical significance

Anemia in patients with Covid-19: pathogenesis and clinical significance

SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients

A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)

Contact Info

Product

Resources

About